The status of plasminogen activator inhibitor-1 as a therapeutic target

Expert Opinion on Investigational Drugs

Volumn 6, Issue 5, 1997, Pages 539-554

  Charlton, P ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

atherosclerosis; cancer; fibrinolysis; inhibitors; plasminogen activator inhibitor 1; plasminogen activators; serpins; thromboembolic disease

Indexed keywords

GEMFIBROZIL; PIPERAZINEDIONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; XR 1853; XR 334; XR 5082; XR 5118;

CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG RESEARCH; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; THROMBOSIS;

EID: 0030918697     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.5.539     Document Type: Review

References (168)